Why Raymond James Says Wall Street Is Underestimating UnitedHealth's Earnings Power

Raymond James upgraded UnitedHealth (UNH) to Outperform from Market Perform with a $330 price target while UNH trades near $272 (down 19.22% YTD and >48% over the past year). The firm cites potential expense upside, Optum Health restructuring (Optum guided ~9% operating earnings growth and ~30 bps margin expansion in 2026) and company guidance toward >$24B operating earnings and a 5.5% operating margin in 2026, plus adjusted EPS guidance above $17.75 vs $16.35 in 2025. Valuation (forward P/E ~20x) and a $8.73 annual dividend (~3% yield) create a contrarian entry, but material risks remain from CMS RADV audits covering ~92% of 2020 Medicare Advantage membership and uncertainty in 2027 Medicare rates.

Analysis

Winners will be vertically integrated services platforms that can turn operating leverage into free cash flow faster than peers; Optum-style scale creates margin optionality through higher-margin care delivery and analytics-led utilization management, which should widen spreads versus standalone insurers and regional health systems. Second-order winners include software and analytics vendors used in value-based care (population health SaaS, risk-adjustment tools) and managed care-friendly specialty pharmacies that capture dispensing margin as hospital outpatient volumes normalize.

Primary tail risks center on regulatory and audit outcomes that can crystallize as balance-sheet reserve events; the timing is non-linear and could compress multiple quarters of earnings if adverse findings trigger retroactive adjustments or slower MA rate growth. Near-term catalysts to watch are sequential margin improvement in the services business and signs of durable utilization improvement at provider partners — those two data points will move the stock more than broad macro headlines in the next 3–12 months.

Consensus underestimates optionality from disentangling unprofitable lines of business and the compounding effect of fixed-cost deleverage inside the services stack; if management converts a modest amount of incremental margin into cash, buybacks and dividend carry could materially shorten the path to fair value. Conversely, the market may still be underpricing a binary legal/regulatory outcome; that asymmetry argues for structured exposure rather than naked directional bets to capture upside while capping tail losses.

Key Decisions for Investors

• Core exposure: Accumulate UNH equity on strength into any reassessment windows (3–12 months) but size initial position at 1–2% of portfolio. Use 9–12 month call spreads (buy 15% OTM / sell 30% OTM) to express bullish view with limited capital — target 2.5x–4x return if services margin reacceleration materializes, max loss = premium paid (~100%).
• Hedged pair: Long UNH / Short ELV (equal dollar) over 6–12 months to isolate services-margin upside from broad managed-care cyclicality. This reduces Medicare-rate and policy risk that hits the entire sector while capturing idiosyncratic re-rating if Optum outperforms peers — risk: if sector-wide rebound occurs, pair may underperform net-long exposure by mid-teens percent.
• Tail protection: Buy 12–18 month UNH put spreads (10–25% OTM buy / 30–40% OTM sell) sized to cover 25–50% of the equity position to cap downside from an adverse RADV/audit outcome. Expect to pay low single-digit percent of notional for this insurance; it limits drawdown while preserving upside.
• Event trade: Small-sized long ahead of next quarterly results focused on services margin commentary (holding period 1–3 months). If management signals sustained margin momentum, add to core position; if commentary is muted or audit exposure grows, close and redeploy to hedged pair or puts.